Search

Your search keyword '"Shati A"' showing total 1,855 results
Start Over Author "Shati A"
1,855 results on '"Shati A"'

56. Using GPU and TPU Hardware Accelerators to Develop a Cloud-Based Genetic Algorithm System

Author

Jabbar, Qabas Abdal Zahraa, Shati, Narjis Mezaal, Ahmed, Nada Thanoon, Mohialden, Yasmin Makki, Angrisani, Leopoldo, Series Editor, Arteaga, Marco, Series Editor, Chakraborty, Samarjit, Series Editor, Chen, Jiming, Series Editor, Chen, Shanben, Series Editor, Chen, Tan Kay, Series Editor, Dillmann, Rüdiger, Series Editor, Duan, Haibin, Series Editor, Ferrari, Gianluigi, Series Editor, Ferre, Manuel, Series Editor, Jabbari, Faryar, Series Editor, Jia, Limin, Series Editor, Kacprzyk, Janusz, Series Editor, Khamis, Alaa, Series Editor, Kroeger, Torsten, Series Editor, Li, Yong, Series Editor, Liang, Qilian, Series Editor, Martín, Ferran, Series Editor, Ming, Tan Cher, Series Editor, Minker, Wolfgang, Series Editor, Misra, Pradeep, Series Editor, Mukhopadhyay, Subhas, Series Editor, Ning, Cun-Zheng, Series Editor, Nishida, Toyoaki, Series Editor, Oneto, Luca, Series Editor, Panigrahi, Bijaya Ketan, Series Editor, Pascucci, Federica, Series Editor, Qin, Yong, Series Editor, Seng, Gan Woon, Series Editor, Speidel, Joachim, Series Editor, Veiga, Germano, Series Editor, Wu, Haitao, Series Editor, Zamboni, Walter, Series Editor, Zhang, Junjie James, Series Editor, Rani, Asha, editor, Kumar, Bhavnesh, editor, Shrivastava, Vivek, editor, and Bansal, Ramesh C., editor

Published
2023
Full Text
View/download PDF

57. Anomaly Detection Techniques in Intelligent Surveillance Systems

Author

Al-Rasheed, Viean Fuaad Abd, Shati, Narjis Mezaal, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Khanna, Ashish, editor, Polkowski, Zdzislaw, editor, and Castillo, Oscar, editor

Published
2023
Full Text
View/download PDF

58. Event Detection on Social Data Streams Using Hybrid-Deep Learning

Author

Mohammed, Mohammed Ali, Shati, Narjis Mezaal, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Khanna, Ashish, editor, Polkowski, Zdzislaw, editor, and Castillo, Oscar, editor

Published
2023
Full Text
View/download PDF

63. From nature to nanotechnology: The interplay of traditional medicine, green chemistry, and biogenic metallic phytonanoparticles in modern healthcare innovation and sustainability

Author

Puri, Abhijeet, Mohite, Popat, Maitra, Swastika, Subramaniyan, Vetriselvan, Kumarasamy, Vinoth, Uti, Daniel E., Sayed, Amany A., El-Demerdash, Fatma M., Algahtani, Mohammad, El-kott, Attalla F., Shati, Ali A., Albaik, Mai, Abdel-Daim, Mohamed M., and Atangwho, Item J.

Published
2024
Full Text
View/download PDF

80. Online Shopping Behaviour in South Africa During the COVID-19 Pandemic

Author

Cullen, Margaret, Calitz, Andre P., Shati, Joseph, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Papagiannidis, Savvas, editor, Alamanos, Eleftherios, editor, Gupta, Suraksha, editor, Dwivedi, Yogesh K., editor, Mäntymäki, Matti, editor, and Pappas, Ilias O., editor

Published
2022
Full Text
View/download PDF

83. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial

Author

Ala Ghobadian, Saba Mokhtari, Behnam Shariati, Leila Kamalzadeh, Mohsen Shati, Mehrdad Eftekhar Ardebili, Masoomeh Yarahmadi, and Mohammadreza Shalbafan

Subjects
Serotonin 5-HT3 receptor, Obsessive-compulsive disorder, Randomized controlled trial, Selective serotonin reuptake inhibitors, Granisetron, Therapeutics. Pharmacology, RM1-950, Toxicology. Poisons, RA1190-1270
Abstract

Abstract Background Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually relieve the severity of symptoms by as much as 20–30%, and satisfactory treatment is obtained in 40–60% of patients with OCD. Nevertheless, the remaining symptoms continue to impair the patients’ function. Therefore, it is necessary to investigate possible strategies to improve the mitigation of symptoms. In this study, the main objective was to examine and investigate the effectiveness of granisetron, which is a serotonin 5-hydroxytryptamine receptor type 3 (5-HT3) antagonist, as an adjunct therapy to selective serotonin reuptake inhibitors, for the purpose of ameliorating OCD symptoms. Methods fifty-eight patients diagnosed with OCD, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, who had a Yale-Brown obsessive-compulsive scale (Y-BOCS) score of more than 21 were recruited in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either granisetron (1 mg twice daily) and sertraline (100 mg daily initially followed by 200 mg daily after week 4) or placebo and sertraline. The primary outcome was OCD symptoms measured by the Y-BOCS. Results Y-BOCS total score significantly dropped in both groups (28.9 to 17.7 for granisetron plus sertraline and 27.5 to 19.3 for placebo plus sertraline group with a slightly greater drop for granisetron plus sertraline group), while the granisetron plus sertraline group experienced a significantly greater reduction in obsession scores (Greenhouse-Geisser F(2.32,97.57) = 4.52,p-value = 0.01). Moreover, in comparison with the placebo plus sertraline group, the proportion of the patients showing complete response was considerably higher among the granisetron plus sertraline group (P-value

Published
2022
Full Text
View/download PDF

84. COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran/[phrase omitted]/[phrase omitted]/Cas, hospitalisations et deces lies a la COVID-19 apres la vaccination: etude de cohorte portant sur la surveillance des evenements en Republique islamique d'Iran/[phrase omitted]/Casos, hospitalizaciones y muertes por la COVID-19 tras la vacunacion: un estudio de cohortes sobre el seguimiento de eventos en la Republica Islamica de Iran

Author

Hosseinzadeh, Ali, Sahab-Negah, Sajad, Nili, Sairan, Aliyari, Roqayeh, Goli, Shahrbanoo, Fereidouni, Mohammad, Alami, Ali, Shati, Mohsen, Ahmadnezhad, Elham, Mehravaran, Shiva, Fateh, Mansooreh, Khajeha, Hamidreza, Emamian, Zahra, Behmanesh, Elahe, Mahdavi, Sepideh, Enayatrad, Mostafa, shahrbabaki, Parvin Mangolian, Ansari-Moghaddam, Alireza, Heidarzadeh, Abtin, Shahraki-Sanavi, Fariba, Shahri, Seyed Mohammad Hashemi, Dehghan, Mahlagha, Moridani, Mohammadreza Amini, Sheibani, Hossein, Abbaszadeh, Maryam, Jafari, Reza, Valikhani, Maryam, Binesh, Ehsan, Vahedi, Hamid, Chaman, Reza, Khodashahi, Rozita, Amini, Mahnaz, Azad, Farahzad Jabbari, Rezaeitalab, Fariborz, Jamehdar, Saeid Amel, Eshraghi, Ali, Sharifi, Hamid, Bajgani, Seyed Mehdi Hashemi, Mahdavi, Amin, Jafarzadeh, Abdollah, Farokhnia, Mehrdad, Ebrahimi, Saeedeh, Pardakhti, Abbas, Ghaderi, Ebrahim, Soltani, Hasan, Jadidoleslami, Sedigh, Arianejad, Anoush, Gavili, Hamed, Moradveisi, Borhan, Motamedi, Dina, Zare, Hamed, Kazemi, Toba, and Emamian, Mohammad Hassan

Subjects
Medical research -- Analysis -- Surveys, Medicine, Experimental -- Analysis -- Surveys, Vaccination -- Analysis -- Surveys, Comorbidity -- Risk factors -- Complications and side effects, Kidney diseases -- Risk factors -- Complications and side effects, Coronaviruses -- Surveys -- Analysis, Health, World Health Organization -- Surveys
Abstract

Objective To investigate the incidence of coronavirus disease 2019 (COVID-19) cases, hospitalizations and deaths in Iranians vaccinated with either AZD1222 Vaxzevria, CovIran[R] vaccine, SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) or Sputnik V. Methods We enrolled individuals 18 years or older receiving their first COVID-19 vaccine dose between April 2021 and January 2022 in seven Iranian cities. Participants completed weekly follow-up surveys for 17 weeks (25 weeks for AZD1222) to report their COVID-19 status and hospitalization. We used Cox regression models to assess risk factors for contracting COVID-19, hospitalization and death. Findings Of 89 783 participants enrolled, incidence rates per 1 000 000 person-days were: 528.2 (95% confidence interval, CI: 514.0-542.7) for contracting COVID-19; 55.8 (95% CI: 51.4-60.5) for hospitalization; and 4.1 (95% CI: 3.0-5.5) for death. Compared with SARS-CoV-2 Vaccine (Vero Cell), hazard ratios (HR) for contracting COVID-19 were: 0.70 (95% CI: 0.61-0.80) with AZD1222; 0.73 (95% CI: 0.62-0.86) with Sputnik V; and 0.73 (95% CI: 0.63-0.86) with Covlran[R]. For hospitalization and death, all vaccines provided similar protection 14 days after the second dose. History of COVID-19 protected against contracting COVID-19 again (HR: 0.76; 95% CI: 0.69-0.84). Diabetes and respiratory, cardiac and renal disease were associated with higher risks of contracting COVID-19 after vaccination. Conclusion The rates of contracting COVID-19 after vaccination were relatively high. SARS-CoV-2 Vaccine (Vero Cell) provided lower protection against COVID-19 than other vaccines. People with comorbidities had higher risks of contracting COVID-19 and hospitalization and should be prioritized for preventive interventions. [phrase omitted] [phrase omitted] Objectif Analyser l'incidence des cas, hospitalisations et deces lies a la maladie a coronavirus 2019 (COVID-19) chez les Iraniens vaccines avec Vaxzevria AZD1222, CovIran[R], le vaccin contre le SARS-CoV-2 (cellule Vero), le vaccin inactive (lnCoV) ou Spoutnik V. Methodes Nous avons recrute des individus de minimum 18 ans ayant recu leur premiere dose de vaccin contre la COVID-19 entre avril 2021 et janvier 2022 dans sept villes iraniennes. Les participants ont rempli des enquetes de suivi hebdomadaires pendant 17 semaines (25 semaines pour AZD1222) afin de communiquer sur leur statut COVID-19 et leur hospitalisation. Nous avons utilise des modeles de regression de Cox pour evaluer les facteurs augmentant les risques de contracter la COVID-19, d'etre hospitalise et de mourir. Resultats Sur 89 783 participants recrutes, le taux d'incidence pour 1 000 000 jours-personnes etait de 528,2 (intervalle de confiance de 95%, IC: 514,0-542,7) en termes d'infection a la COVID-19; de 55,8 (IC de 95%: 51,4-60,5) en termes d'hospitalisation; et de 4,1 (IC de 95%: 3,0-5,5) en termes de deces. Compare au vaccin contre le SARS-CoV-2 (cellule Vero), le rapport de risque (RR) de contracter la COVID-19 s'elevait a 0,70 (IC de 95%: 0,61-0,80) avec AZD1222; a 0,73 (IC de 95%: 0,62-0,86) avec Spoutnik V; et a 0,73 (IC de 95%: 0,63-0,86) avec CovIran[R]. Concernant l'hospitalisation et le deces, tous les vaccins offraient un niveau de protection similaire 14 jours apres la seconde dose. Avoir contracte la COVID-19 par le passe premunissait contre une reinfection (RR: 0,76; IC de 95%: 0,69-0,84). Le diabete et les maladies respiratoires, cardiaques et renales entrainaient un risque accru de contracter la COVID-19 apres la vaccination. Conclusion Le taux d'infection a la COVID-19 apres la vaccination etait relativement eleve. D'autre part, le vaccin contre le SARS-CoV-2 (cellule Vero) s'est revele moins efficace que les autres vaccins. Enfin, les personnes souffrant de comorbidites avaient plus de risques de contracter la COVID-19 et d'etre hospitalisees; elles devraient donc etre prioritaires lors des interventions preventives. [phrase omitted] Objetivo Analizar la Incidencia de los casos, hospitalizaciones y muertes a causa de la enfermedad por coronavirus de 2019 (COVID-19) en los iranies vacunados con Vaxzevria AZD1222, la vacuna CovIran[R], la vacuna contra el SARS-CoV-2 (celula Vero), la vacuna inactivada (lnCoV) o la Sputnik V. Metodos Se inscribieron personas de 18 anos o mas que recibieron su primera dosis de la vacuna contra la COVID-19 entre abril de 2021 y enero de 2022 en siete ciudades iranies. Los participantes completaron encuestas de seguimiento semanales durante 17 semanas (25 semanas para AZD1222) para informar sobre su estado de la COVID-19 y la hospitalizacion. Se utilizaron modelos de regresion de Cox para valorar los factores de riesgo de contraer la COVID-19, de ser hospitalizado y de morir. Resultados De los 89 783 participantes inscritos, las tasas de incidencia por 1 000 000 de dias-persona fueron 528,2 (intervalo de confianza del 95 %, IC: 514,0-542,7) en el caso de contraer la COVID-19; 55,8 (IC del 95 %: 51,4-60,5) en el caso de hospitalizacion; y 4,1 (IC del 95 %: 3,0-5,5) en el caso de muerte. En comparacion con la vacuna contra el SARS-CoV-2 (celula Vero), los cocientes de riesgos instantaneos (CRI) de contraer la COVID-19 fueron 0,70 (IC 95 %: 0,61-0,80) con AZD1222; 0,73 (IC 95 %: 0,62-0,86) con Sputnik V; y 0,73 (IC 95 %: 0,63-0,86) con CovIran[R]. En cuanto a la hospitalizacion y la muerte, todas las vacunas proporcionaron una proteccion similar 14 dias despues de la segunda dosis. Los antecedentes de la COVID-19 protegieron contra la contraccion de la COVID-19 de nuevo (CRI: 0,76; IC 95 %: 0,69-0,84). La diabetes y las enfermedades respiratorias, cardiacas y renales se asociaron a un mayor riesgo de contraer la COVID-19 despues de la vacunacion. Conclusion Las tasas de contraer la COVID-19 despues de la vacunacion fueron relativamente altas. La vacuna contra el SARS-CoV-2 (celula Vero) proporciono una menor proteccion contra la COVID-19 que otras vacunas. Las personas con comorbilidades tenian un mayor riesgo de contraer la COVID-19 y de ser hospitalizadas, por lo que deberian ser prioritarias para las intervenciones preventivas., Introduction To end the ongoing global pandemic of coronavirus disease 2019 (COVID-19), it is imperative to have safe and effective vaccines that can provide immunity against severe acute respiratory syndrome [...]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results